Emese Zsiros, MD, PhD, FACOG

According to Emese Zsiros, MD, PhD, FACOG, the pembrolizumab regimen yields favorable responses and survival in this PROC population.

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.